Top

Gepubliceerd in:

01-11-2007 | Editorial

Does glycoprotein IIB/IIIA resistance exist?

Auteurs: J. J. J. Smit, A. W. J. van’t Hof

Gepubliceerd in: Netherlands Heart Journal | Uitgave 11/2007

Abstract

Platelet function testing is not embedded into routine clinical practice, because no optimal, easy, reproducible and multipathway platelet aggregation test can be accomplished in vitro. Only recently, the relationship between the level of platelet aggregation inhibition by platelet inhibitors and clinical outcome in acute myocardial infarction became more clear.1-5 High platelet reactivity was found in patients who experienced stent thrombosis, and patients with clopidogrel resistance were at increased risk of recurrent atherothrombotic events.1,2 Furthermore, in ST-elevation myocardial infarction (STEMI) increased levels of platelet aggregation were found compared with unstable angina or control patients.4 In a thrombolysis study, higher platelet receptor occupancy was coupled with better angiographic and electrocardiographic outcome.

volgende artikel Long-term prognostic value of CFVR and FFR versus perfusion scintigraphy in patients with multivessel disease

Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-5.

Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005;46:1827-32.

Gibson CM, Jennings LK, Murphy SA, Lorenz DP, Giugliano RP, Harrington RA, et al. for the INTEGRITI Study Group. Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and STsegment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy. Circulation 2004;110:679-84.

Frossard M, Fuchs I, Leitner JM, Hsieh K, Vlcek M, Losert H, et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 2004;110:1392-7.

de Prado AP, Fernandez-Vazquez F, Cuellas JC, Alonso-Orcajo N, Carbonell R, Pascual C, et al. Association between level of platelet inhibition after early use of abciximab and myocardial reperfusion in ST-elevation acute myocardial Infarction treated by primary percutaneous coronary intervention. Am J Cardiol 2006;97:798-803.

van Werkum JW, Gerritsen WBM, Kelder JC, Hackeng CM, Deneer VHM, Suttorp MJ, et al. Inhibition of platelet function by abciximab or high-dose tirofiban in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial. Neth Heart J 2007;15:375-81.

Schneider DJ, Herrmann HC, Lakkis N, Aguirre F, Wan Y, Aggarwal A, et al. Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban. Am J Cardiol 2002;90:1421-1424.

Kabbani SS, Aggarwal A, Terrien EF, DiBattiste PM, Sobel BE, Schneider DJ. Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am J Cardiol 2002;89:647-50.

Harrington RA, Kleiman NS, Kottke-Marchant K, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995;76:1222-7.

10.

Tcheng JE, Ellis SG, George BS, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994;90:1757-64.

11.

Ernst NMSKJ, Suryapranata H, Miedema K, et al. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST segment elevation myocardial infarction. J Am Coll Cardiol 2004;44:1187-93.

12.

Smit JJJ, Hoorntje JCA, Miedema K, van Oeveren W. Impaired platelet inhibitory effect of a single dose acetylsalicylic acid in patients with unstable coronary artery syndrome in comparison with healthy volunteers. Neth Heart J 2004;12:265-70.

13.

Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007;115:3156-64.

14.

Rocca B, Patrono C. Determinants of the interindividual variability in response to antiplatelet drugs. J Thromb Haemost 2005;3:1597-602.

15.

Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 ndividuals. J Am Coll Cardiol 2005;45(2):246-51.

16.

Van ’t Hof AWJ, Hamm C, Rasoul S, et al. Ongoing tirofiban in myocardial infarction evaluation (On-TIME) 2 trial: rationale and study design. Eurointervention 2007, published online, ahead of print.

Titel: Does glycoprotein IIB/IIIA resistance exist?
Auteurs: J. J. J. Smit
A. W. J. van’t Hof
Publicatiedatum: 01-11-2007
Uitgeverij: Bohn Stafleu van Loghum
Gepubliceerd in: Netherlands Heart Journal / Uitgave 11/2007
Print ISSN: 1568-5888
Elektronisch ISSN: 1876-6250
DOI: https://doi.org/10.1007/BF03086016

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen

Andere artikelen Uitgave 11/2007

Transvenous pacing after the Mustard procedure: considering the complications

Images in cardiovascular medicine: Transkei heart

Stent thrombosis in real-world patients: a comparison of drug-eluting with bare metal stents

Coronary stent healing, endothelialisation and the role of co-medication

Inhibition of platelet function by abciximab or high-dose tirofiban in patients with STEMI undergoing primary PCI: a randomised trial

Long-term prognostic value of CFVR and FFR versus perfusion scintigraphy in patients with multivessel disease